Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The findings represent an important proof-of-concept for the compound as there are currently no Food and Drug Administration-approved treatments for NAFLD and NASH.
Search for any Health Related Issue
Silent KIller: Inflamation
Traditional Cancer Treatments Create Inflammation and Promoting Tumor Growth Chemotherapy that kills cancer cells can also trigger an inflammatory response that actually promotes aggressive tumor growth. 1097  0 Inflammation Chronic Disease May Be Triggered By Repeated Food Poisoning
Cancer Traditional Cancer Treatments Create Inflammation and Promoting Tumor Growth ..
- Portable brain imaging system to shed light on concussions
- Vaginal health and hygiene practices and product use in Canada: a national cross-sectional survey
- Is knee pain linked to depression?
- Older adults who have slower walking speeds may have increased risk for dementia
- Mutations of the bassoon gene causing new brain disorder